Quantitative immunology protein panel built on the SomaScan® Assay platform
Abstract
The SomaScan® Assay is a highly multiplexed proteomic assay that uses SOMAmer® Reagents to detect proteins in various biological samples. The latest version of the SomaScan Assay allows researchers to profile 11,000 protein measurements in human blood. The SomaScan Assay is designed to provide protein epitope abundance measurements by reporting relative SOMAmer Reagent abundance quantified using DNA microarrays. This is common for highly multiplexed proteomic assays but different from clinical protein assays, which report protein concentrations. We set out to develop a Quantitative Immunology Protein Panel (QuIPP) built on the SomaScan 7K Assay, focused on a set of 58 immunologically-relevant cytokines, chemokines, and growth factors. Panel qualification was performed by developing calibration curves and demonstrating reproducibility for the biomarker measurements in serum samples with defined LLOQ and ULOQ acceptance criteria. Intra-run and inter-run CVs were calculated for high, medium, and low QC samples. 54 analytes met the standard curve, QC sample reproducibility, and plate edge effect acceptance criteria, with 34 analytes meeting strict parallelism acceptance criteria.
We have demonstrated the process for developing the QuIPP using SomaScan Assay as a core technology. The ability to generate quantitative results will allow the SomaScan Assay users to compare protein concentrations across datasets and further validate biomarker discoveries on the SomaScan Platform.
Authors
Evaldas Katilius1
Tracy Keeney1
Eduardo Tabacman1
Rong Liu2
Graham Yearwood2
Peter Schafer2
1Standard BioTools Inc
2Bristol Myers Squibb, Princeton, New Jersey
See the poster presented at Immunology 2024
Download the poster here after May 5th, 2024
More posters
PosterComparison of Proteomic CV Risk to Established ASCVD 10-Year Risk Decision Points
The ASCVD pooled cohort equation (PCE) is well-established for CV risk assessment. Decision points for determining treatment plans are low, intermediate and high risk over 10 years, however this approach over and underestimates risk in certain subgroups. The validated CV Risk SomaSignal® Test (SST) provides 4-year risk probability of MACE allowing for timely assessment of risk, but the shorter timescale makes comparison to 10-year PCE risk less intuitive.
PosterStatin signature: using proteomics to detect pharmacological fingerprints
Using a previously described metacohort (n=5,575) of patients with increased CV risk, we hypothesized that PCE would stratify patients differently than the CV Risk SST, and that CV Risk score scaled to 10 years would yield an improved net reclassification index (NRI).
PosterUsing a proteomics-based cardiovascular risk test to identify systemic changes in a clinical trial of nonalcoholic fatty liver disease
Improvement in hepaKc inflammaKon, NAFLD acKvity score and fibrosis were associated with improved proteomic CV risk scores regardless of treatment provided.